✦ LIBER ✦

S47. Tumour infiltrating lymphocytes - a predictive marker?

✍ Scribed by Galon, J

Book ID: 125405033
Publisher: Springer (Biomed Central Ltd.)
Year: 2014
Tongue: English
Weight: 77 KB
Volume: 2
Category: Article
ISSN: 2051-1426
DOI: 10.1186/2051-1426-2-S2-I10

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stromal metachromasia: a marker for area

Stromal metachromasia: a marker for areas of infiltrating tumour growth?

✍ F. HARTVEIT; E. SANDSTAD 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 439 KB

S76. Adoptive cell therapy of melanoma w

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes

✍ Svane, I; Andersen, R; Donia, M 📂 Article 📅 2014 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 74 KB

Tumor-infiltrating lymphocytes are a mar

Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma

✍ Thomas C. Smyrk; Patrice Watson; Karen Kaul; Henry T. Lynch 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

Computerised counting of tumour infiltra

Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens

✍ S. Marsigliante; L. Biscozzo; A. Marra; G. Nicolardi; G. Leo; G.B. Lobreglio; C. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 449 KB

Quantifying tumour-infiltrating lymphocy

Quantifying tumour-infiltrating lymphocyte subsets: A practical immuno-histochemical method

✍ Paula M. Loughlin; Timothy G. Cooke; W. David George; Alison J. Gray; David I. S 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 768 KB

TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARK

TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN INFILTRATING LOBULAR CARCINOMA OF THE BREAST

✍ MORPHOPOULOS, G.; PEARSON, M.; RYDER, W. D. J.; HOWELL, A.; HARRIS, M. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 626 KB

The importance of angiogenesis, assessed by tumour microvessel density, as a marker of survival was examined in 160 patients with infiltrating lobular carcinoma of the breast (ILC). The median follow-up was 5.1 years. Of these patients, 46 were node-negative, 59 were node-positive, and in 55 the pat